Clinical Trial

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2020-02-11; most recent amendment 2026-06-18.
Status change: Active, Not Recruiting → Completed 2026-06-18
Status change: Suspended → Active, Not Recruiting 2025-12-11
Status change: Recruiting → Suspended 2025-11-13
Status change: Not Yet Recruiting → Recruiting 2020-05-18
Trial Details
NCT Number NCT04269213
Lead Sponsor Roswell Park Cancer Institute
Collaborators: Jazz Pharmaceuticals
Conditions Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Enrollment 21 participants
Start Date 2021-07-29
Primary Completion 2025-04-10 (estimated)
Study Completion 2027-01-29 (estimated)
Updated on ClinicalTrials.gov 2025-12-23